Kirk Nicholas Campbell, MD

Renal Electrolyte and Hypertension
Accepting new patients
Sees patients age 18 and up
Penn Renal Electrolyte and Hypertension Perelman
Headshot of Kirk Nicholas Campbell, MD
Penn Medicine Provider

About me

  • Chief, Division of Renal-Electrolyte and Hypertension
  • C. Mahlon Kline Professor

My education and training

  • Residency: Yale-New Haven Hospital
  • Fellowship: Mount Sinai Medical Center

Spoken languages

English
English

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Campbell is a Penn Medicine physician.

Qualifications and experience

Treatments and conditions

Research

Publications

Mohandes S, Nast CC, Mottl A, Scialla J, Almaani S, Luciano R, Isakova T, Ellis C, Bansal S, Argyropoulos C, Jennette JC, Gasim A, Stillman IE, Campbell KN, Abedini A, Coppock G; TRIDENT Consortium; Susztak K, Palmer MB. Improving the Histologic Classification of Advanced Diabetic Nephropathy Based on the Transformative Research in Diabetic Nephropathy (TRIDENT) Findings , Kidney Int: 2026


Mohandes S, Fakhreddine M, Sheng H, Al Dulaimee M, Mottl A, Scialla J, Almaani S, Luciano R, Isakova T, Bansal S, Argyropoulos C, Avasare R, Singh M, Campbell KN, Townsend R, Coppock G, Palmer M, Susztak K; TRIDENT Consortium. Percutaneous Native Kidney Biopsy Complications in Diabetic Patients in the TRIDENT Cohort , Clin J Am Soc Nephrol, 21: 2026,1376-1385


Heerspink HJL, Arnott C, Barratt J, Campbell KN, Pecoits-Filho R, Fukami K, Halimi JM, Hou FF, Lam CSP, Levin A, Lindberg M, Kashioulis P, Mercier AK, Sinsakul M, Ambery P, Perkovic V. Design and baseline characteristics of the ZENITH high proteinuria trial testing zibotentan/dapagliflozin efficacy in CKD , Nephrol Dial Transplant: 2026


Vasquez-Rios G, Chauhan K, Naik N, Pattharanitima P, Chan L, Campbell KN, Nadkarni GN, Coca SG. Beyond Genotype: Multidomain Biomarker-Integrated Risk Scores Reveal Prognostic phenotypes Among Individuals with High-Risk APOL1 Genotypes , medRxiv: 2026


Lafayette R, Barbour SJ, Brenner RM, Campbell KN, Doan T, Eren N, Floege J, Jha V, Kim BS, Liew A, Maes B, Pal A, Pecoits-Filho R, Phoon RKS, Rizk DV, Suzuki H, Tesař V, Trimarchi H, Wei X, Zhang H, Barratt J; ORIGIN Phase 3 Trial Investigators. A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy , N Engl J Med, 394: 2026,647-657


Floege J, Ayoub I, Brix SR, Campbell KN, Furie R, Nachman PH, Tang SCW, Tomas NM, Vivarelli M, Cheung M, King JM, Grams ME, Jadoul M, Rovin BH; Conference Participants. Targeting B cells in immune-mediated kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference , Kidney Int: 2026


Fischman CJ, Zee J, Campbell KN. Family Matters: Dissecting the Impact of Family Medical History, APOL1 Genotype, and Sociodemographic Factors on CKD Progression in the Chronic Renal Insufficiency Cohort (CRIC) Study , Am J Kidney Dis: 2026


Yu L, Ekperikpe US, Korsmo HW, Zhao S, Yi Z, Haydak J, Lefferts S, Meliambro K, Campbell KN, Azeloglu EU, Kohan DE, McCown PJ, Naik AS, Otto EA, Haraldsson B, Zhang W, Daehn IS. Podocyte-derived endothelin-1 and endothelial cell endothelin A receptors are essential for glomerular injury in mouse models of focal segmental glomerulosclerosis , Kidney Int: 2026


Wong JS, Campbell KN. Communication leading to injury: podocyte-derived fibrillin-1 induces mesangial cell activation and proliferation through EGFR signaling , Kidney Int: 2026


Sanchez-Russo L, Vasquez-Rios G, Campbell KN. Podocyte-Targeted Therapy in Focal Segmental Glomerulosclerosis: Insights From a Phase 2 Trial of TRPC6 Inhibition , Am J Kidney Dis: 2026